drugset / Trial / NCT04104646

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

NCT04104646

Phase 2 Terminated 7 enrolled Chiesi Farmaceutici S.p.A.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase II, multicenter, double blind, double dummy, randomized, 2 arms parallel study to evaluate the efficacy, safety and pharmacokinetics of CHF6563 in babies with Neonatal Opioid Withdrawal Syndrome

Timeline

Start
2020-12-18
Primary completion
2021-12-13
Completion
2021-12-13

Drugs

EvaluationDrugModalityDoseRoute
Subject CHF6563 Unknown 10 ug/kg Subcutaneous
Subject CHF6563 Unknown 90 ug/kg Subcutaneous
Comparator Morphine Other / unclassified 0.07 mg/kg Oral